Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China
Hongting Yao,1 Kai Xu,1 Man Yu,1 Xiaoye Wang,2 Yingzhi Lu,3 Xin Li,1,2,4,5 Hong Wu6 1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, People’s Republic of China; 2Department of Health Policy, School of Health Policy and M...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Risk Management and Healthcare Policy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-analysis-of-serplulimab-combined-with-nab-paclitaxe-peer-reviewed-fulltext-article-RMHP |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|